To **Date:** 06/08/2026

The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 544759, Scrip ID: GLPL,

Sub: Intimation of Notice of 22nd Annual General Meeting of Goldline Pharmaceutical Limited.

Sir / Ma'am,

We wish to inform the Exchange that the 22nd Annual General Meeting (AGM) of Goldline Pharmaceutical Limited will be held on Saturday, 29th August, 2026 at 4:00 P.M. at Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025.

The copy of Notice of 22nd Annual General Meeting (AGM) of the company is enclosed herewith.

The same is for your information and record.

Thanking you,

Yours faithfully,

FOR GOLDLINE PHARMACEUTICAL LIMITED

Ruchi Sanket Modi
Digitally signed by Ruchi Sanket Modi
Date: 2026.08.06 18:10:31 +05'30'

Ruchi Sanket Modi
Company Secretary cum Compliance Officer

NOTICE

Notice is hereby given that the 22nd Annual General Meeting of the members of Goldline Pharmaceutical Limited (CIN: L51397MH2004PLC147806) will be held on Saturday, 29th August, 2026 at 4:00 P.M at the Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025 to consider the following business:

ORDINARY BUSINESS:

ITEM NO. 01 - Adoption of Audited Financial Statements

To receive, consider and adopt the Standalone Audited Balance Sheet for the year ended 31st March, 2026, the Profit and Loss account for the year ended as on the said date, Cash Flow Statement, Auditors' Report and the Directors' Report thereon.

ITEM NO. 02 - Declaration of Dividend on Preference Shares

To declare dividend on preference shares for the financial year 2025-26.

ITEM NO. 03 - Re-appointment of a Director

To re-appoint Mr. Prashant Shrikrishna Karkare, Director (DIN: 06572686) who retires by rotation and being eligible, offers himself for the re- appointment.

To consider and, if thought fit, to pass the following resolution, with or without modification as an **Ordinary Resolution**:

"RESOLVED THAT Mr. Prashant Shrikrishna Karkare, Director (DIN: 06572686), who retires by rotation in terms of Section 152 of Companies Act, 2013 and being eligible be and is hereby re-appointed as Executive Director of the Company whose office shall be liable to retirement by rotation.

SPECIAL BUSINESS:

ITEM NO. 04 - To approve existing as well as new material related party transactions with Activista Healthcare Private Limited:

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, the applicable provisions of the Companies Act, 2013 ("the Act") read with the rules framed thereunder, other applicable laws including any amendments, modifications or re-enactments thereof from time to time, the Company's Policy on Related Party Transactions, and subject to such approvals, consents, and permissions as may be required, the approval of the shareholders of the Company be and is hereby accorded to enter into and/or continue with existing and new material related party transaction(s), contract(s), arrangement(s) or agreement(s), whether entered individually or in aggregate or as part of a series, with Activista Healthcare Private Limited, Indore, is a Enterprises over which relatives of KMP are able to exercise significant influence and a related party as per Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations, during the financial year ending March 31, 2026, on such material terms and conditions as specified in the Explanatory Statement to this resolution and as may be mutually agreed upon by the Company and the related party, provided that such transactions shall be undertaken in the ordinary course of business and on an arm's length basis.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the "Board", which term shall be deemed to include the Audit Committee and/or any other Committee duly constituted or to be constituted by the Board), be and is hereby authorised to do all such acts, deeds, matters, and things as may be necessary, desirable or expedient to give effect to this resolution including finalising and executing agreements, documents, applications and other writings, seeking approvals as may be required, and to delegate all or any of its powers herein conferred to any Committee or any director(s) or officer(s) of the Company as it may in its absolute discretion deem fit, without seeking any further approval of the shareholders."

RESOLVED FURTHER THAT all actions taken or to be taken by the Board or any officer of the Company in connection with the transactions referred to in this resolution be and are hereby approved, confirmed and ratified in all respects."

ITEM NO. 05 - To approve existing as well as new material related party transactions with Nucleage Pharma Solutions Private Limited:

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, the applicable provisions of the Companies Act, 2013 ("the Act") read with the rules framed thereunder, other applicable laws including any amendments, modifications or re-enactments thereof from time to time, the Company's Policy on Related Party Transactions, and subject to such approvals, consents, and permissions as may be required, the approval of the shareholders of the Company be and is hereby accorded to enter into and/or continue with existing and new material related party transaction(s), contract(s), arrangement(s) or agreement(s), whether entered individually or in aggregate or as part of a series, with Nucleage Pharma Solutions Private Limited, Indore, is a Enterprises over which relatives of KMP are able to exercise significant influence and a related party as per Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations, during the financial year ending March 31, 2026, on such material terms and conditions as specified in the Explanatory Statement to this resolution and as may be mutually agreed upon by the Company and the related party, provided that such transactions shall be undertaken in the ordinary course of business and on an arm's length basis.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the "Board", which term shall be deemed to include the Audit Committee and/or any other Committee duly constituted or to be constituted by the Board), be and is hereby authorised to do all such acts, deeds, matters, and things as may be necessary, desirable or expedient to give effect to this resolution including finalising and executing agreements, documents, applications and other writings, seeking approvals as may be required, and to delegate all or any of its powers herein conferred to any Committee or any director(s) or officer(s) of the Company as it may in its absolute discretion deem fit, without seeking any further approval of the shareholders."

RESOLVED FURTHER THAT all actions taken or to be taken by the Board or any officer of the Company in connection with the transactions referred to in this resolution be and are hereby approved, confirmed and ratified in all respects."

ITEM NO. 06 - To approve existing as well as new material related party transactions with Numerius Healthcare Private Limited:

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, the applicable provisions of the Companies Act, 2013 ("the Act") read with the rules framed thereunder, other applicable laws including any amendments, modifications or re-enactments thereof from time to time, the Company's Policy on Related Party Transactions, and subject to such approvals, consents, and permissions as may be required, the approval of the shareholders of the Company be and is hereby accorded to enter into and/or continue with existing and new material related party transaction(s), contract(s), arrangement(s) or agreement(s), whether entered individually or in aggregate or as part of a series, with Numerius Healthcare Private Limited, Indore, is a Enterprises over which relatives of KMP are able to exercise significant influence and a related party as per Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations, during the financial year ending March 31, 2026, on such material terms and conditions as specified in the Explanatory Statement to this resolution and as may be mutually agreed upon by the Company and the related party, provided that such transactions shall be undertaken in the ordinary course of business and on an arm's length basis.

RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as the “Board”, which term shall be deemed to include the Audit Committee and/or any other Committee duly constituted or to be constituted by the Board), be and is hereby authorised to do all such acts, deeds, matters, and things as may be necessary, desirable or expedient to give effect to this resolution including finalising and executing agreements, documents, applications and other writings, seeking approvals as may be required, and to delegate all or any of its powers herein conferred to any Committee or any director(s) or officer(s) of the Company as it may in its absolute discretion deem fit, without seeking any further approval of the shareholders.”

RESOLVED FURTHER THAT all actions taken or to be taken by the Board or any officer of the Company in connection with the transactions referred to in this resolution be and are hereby approved, confirmed and ratified in all respects.”

ITEM NO. 07 - Borrowing of Unsecured Loan from directors with an Option of Convertibility into Equity Shares:

To consider and, if thought fit, to pass the following resolution, with or without modification as **Special Resolution:**

“RESOLVED THAT pursuant to recommendation of Audit Committee and Section 62 (3) and other applicable provisions, if any, of the Companies Act, 2013 and Rules made there under and in accordance with the Memorandum and Articles of Association of the Company and subject to all such approval(s), consent(s), permission(s), sanction(s), if any, the consent of members be and is hereby accorded to borrow unsecured loan from the Directors of the Company as and when required subject to overall limit of borrowing of Rs. 200 Crores as sanctioned under Section 180 (1) (c) of the Companies Act, 2013.

RESOLVED FURTHER THAT the conversion right attached with the unsecured loan of Directors be and is hereby approved pursuant to following terms being agreed between the Company and its Directors to convert the whole or part of the outstanding loans at the option of Directors into fully paid-up equity shares of the Company.

Terms and Conditions:

I. the conversion right reserved as aforesaid may be exercised by the Directors during the continuation of loan;

II. on receipt of the notice of conversion, the Company shall subject to the terms being entered, allot and issue the requisite number of fully paid-up equity shares to the Directors and the Directors may accept the same in satisfaction of the part of the loans so converted;

III. the part of the loan so converted shall cease to carry interest as from the date of conversion and the loan shall stand correspondingly reduced. Upon such conversion, the repayment instalments of the loan payable after the date of conversion as per the terms shall stand reduced proportionately by the amount of the loan so converted. The equity shares so allotted and issued to the Directors shall rank pari passu with the existing equity shares of the Company in all respects.

IV. in the event the Directors exercise the conversion right as aforesaid, the Company shall at its cost get the equity shares, issued to the Directors and list the shares on the Stock exchanges where Company's shares are presently listed and for the said purpose the Company shall take all such steps as may be necessary to ensure that the equity shares are listed on the Stock Exchanges.

V. the loan shall be converted into equity shares at a price to be determined in accordance with the applicable Securities and Exchange Board of India Regulations at the time of such conversion.

VI. the equity shares so allotted pursuant to conversion shall call carry right to receive the dividends and other distributions to be declared in respect of paid-up equity share capital of the Company.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, any Director of the Board be and is hereby authorised to do all such acts, deeds, matters and things, as may in absolute discretion deemed necessary, proper or desirable and to dematerialize the shares of the Company and to resolve and settle any question, difficulty or doubt that may arise in this regard and to do all such other acts, deeds, matters and things in connection with or incidental thereto."

ITEM NO. 08 - Approval of loans, investments, guarantee or security u/s 185 of Companies Act, 2013:

To consider and, if thought fit, to pass the following resolution, with or without modification as **Special Resolution:**

"RESOLVED THAT, pursuant to Section 185 and all other applicable provisions of the Companies Act, 2013 and Rules made thereunder as amended from time to time, the consent of the members of the Company be and is hereby accorded to authorize the Board of Directors of the Company (here in after referred to as the Board, which term shall be deemed to include, unless the context otherwise required, any committee of the Board or any director or officer(s) authorised by the Board to exercise the powers conferred on the Board under this resolution) to advance any loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any entity which is a subsidiary or associate or joint venture of the company, (in which any director is deemed to be interested) or to Managing Director or Whole time director of the company upto an aggregate sum of INR 200 Crores (Rupees Two Hundred Crores Only) in their absolute discretion deem beneficial and in the interest of the Company, provided that such loans are utilized by the borrowing company for its principal business activities.

RESOLVED FURTHER THAT, for the purpose of giving effect to this resolution the Board of Directors of the Company be and are hereby authorised to do all acts, deeds and things in their absolute discretion that may be considered necessary, proper and expedient or incidental for the purpose of giving effect to this resolution in the interest of the Company."

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

SD/-

Name: Amol Laxmikant Mujumdar

DIN: 01910549

Designation: Managing Director

Date: 06/08/2026

Place: Nagpur

Route Map

Address: Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025.

https://www.google.com/maps/place/Hotel+Airport+Centre+Point/@21.0943513,79.0629032,782m/data=!3m2!1e3!5s0x3bd4bf0ac2e193fb:0x31a31f5c01698ec3!4m9!3m8!1s0x3bd4bf0a88cf0489:0xf12400f357e0e43b!5m2!4m1!1i2!8m2!3d21.0943513!4d79.0654781!16s%2Fg%2F12vsj6xyq?entry=ttu&g_ep=EgoyMDI2MDcyOS4wIKXMDSoASAFQAw%3D%3D



NOTES:

1. A member entitled to attend and vote at the meeting is entitled to appoint proxy/proxies to attend and vote instead of himself/herself. Such proxy/proxies need not to be a member of the company.
2. A person can act as proxy on behalf of members not exceeding (50) and holding in the aggregate not more than ten percent of the total share capital of the Company. In case a proxy is proposed to be appointed by a Member holding more than 10% of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or shareholder.
3. The instrument of Proxy in order to be effective, should be deposited at the registered office of the Company, duly completed and signed, not less than 48 hours before the commencement of the meeting.
4. A Proxy form is sent herewith. Proxies submitted on behalf of the companies, societies, etc., must be supported by an appropriate resolution authority, as applicable.
5. Corporate Members are requested to send a duly certified copy of the Board Resolution/Power of Attorney/Letter of Representation authorizing its representative to attend and vote on their behalf at the Annual General Meeting.
6. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.
7. During the 22nd AGM, Members may access the scanned copy of Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, the Register of Contracts and Arrangements in which Directors are interested maintained under Section 189 of the Act.
8. **DISPATCH OF ANNUAL REPORT THROUGH ELECTRONIC MODE**:

   In line with the SEBI Circular dated January 5, 2023, the Notice of the AGM along with the Annual Report, indicating the process and manner of voting through electronic means is being sent only through electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories. The Notice convening the 22nd AGM along with Annual Report for the financial year 2025-26 has been uploaded on the website of the Company at www.goldlinepharma.in under 'Investor Information' section and may also be accessed on the websites of the Stock Exchanges i.e. the Bombay Stock Exchange of India Limited at https://www.bseindia.com/.

9. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended) the Company is providing facility of remote e-voting to its members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Bigshare Services Private Limited for facilitating voting through electronic means, as the authorized agency. The facility for voting through Ballot/Polling Paper shall also be made available at the meeting and Members attending the meeting who have not already cast their vote by remote e-voting shall be able to exercise their right at the meeting by Ballot/Polling Paper. The Board has appointed **M/s Avinash Gandhewar & Associates**, Practicing Company Secretaries, Nagpur, as a Scrutinizer to scrutinize the process of e-voting.

10. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any Member as soon as possible. Members are also advised to not leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant and holdings should be verified from time to time.

11. Non-Resident Indian Members are requested to inform the Company's RTA immediately of:

a. Change in their residential status on return to India for permanent settlement.

b. Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.

12. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, Permanent Account Number ('PAN'), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc.

- **For shares held in electronic form:** to their Depository Participants only and not to the Company's RTA. Changes intimated to the Depository Participants will then be automatically reflected in the Company's records which will help the Company and its RTA provide efficient and better service to the Members.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER: -

i. The voting period begins on Tuesday 25th August, 2026 9:00 AM and ends on Friday, 28th August, 2026 till 5:00 PM. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Saturday, 22nd August, 2026 may cast their vote electronically. The e-voting module shall be disabled by Bigshare for voting thereafter.

ii. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

iii. Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020,** under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders**, **by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

iv. In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular**,** Login method for e-Voting **for Individual shareholders holding securities in Demat mode** is given below:

Type of shareholders	**Login Method**
Individual Shareholders holding securities in Demat mode with **CDSL**	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi/Easiest is https://web.cdslindia.com/myeasitoken/home/login or visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then use your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of **BIGSHARE** the e-Voting service provider and you will be re-directed to **i-Vote** website for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. **BIGSHARE**, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasitoken/Registration/EasiRegistration 4. Alternatively, the user can directly access e-Voting page by providing Demat

	Account Number and PAN No. from a link https://evoting.cdslindia.com/Evoting/EvotingLogin The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress, and also able to directly access the system of all e-Voting Service Providers. Click on **BIGSHARE** and you will be re-directed to **i-Vote** website for casting your vote during the remote e-voting period.
Individual Shareholders holding securities in demat mode with **NSDL**	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name **BIGSHARE** and you will be re-directed to **i-Vote** website for casting your vote during the remote e-Voting period. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS “Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting

	page. Click on company name or e-Voting service provider name **BIGSHARE** and you will be redirected to **i-Vote** website for casting your vote during the remote e-Voting period. 4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page with all e-Voting Service Providers. Click on **BIGSHARE** and you will be re-directed to **i-vote (E-voting website)** for casting your vote during the remote e-Voting period.
Individual Shareholders (holding securities in demat mode) login through their **Depository Participants**	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with **CDSL**	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free No. 1800 22 55 33.
Individual Shareholders holding securities in Demat mode with **NSDL**	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022- 48867000.

1. **Login method for e-Voting for shareholder other than individual shareholders holding shares in Demat mode & physical mode is given below:**

- You are requested to launch the URL on internet browser: https://ivote.bigshareonline.com
- Click on "**LOGIN**" button under the '**INVESTOR LOGIN**' section to Login on E-Voting Platform.
- Please enter you '**USER ID'** (User id description is given below) and '**PASSWORD'** which is shared separately on you register email id.

  - Shareholders holding shares in **CDSL demat account should enter 16 Digit Beneficiary ID** as user id.
  - Shareholders holding shares in **NSDL demat account should enter 8 Character DP ID followed by 8 Digit Client ID** as user id.
  - Shareholders holding shares in **physical form should enter Event No + Folio Number** registered with the Company as user id.

Note *If you have not received any user id or password, please email from your registered email id or contact i-vote helpdesk team. (Email id and contact number are mentioned in helpdesk section).*

- Click on **I AM NOT A ROBOT (CAPTCHA)** option and login.

  NOTE: If Shareholders are holding shares in demat form and have registered on to e-Voting system of https://ivote.bigshareonline.com and/or voted on an earlier event of any company then they can use their existing user id and password to login.

- If you have forgotten the password: Click on '**LOGIN**' under '**INVESTOR LOGIN**' tab and then Click on '**Forgot your password**?
- Enter "**User ID"** and "**Registered email ID**" Click on **I AM NOT A ROBOT (CAPTCHA)** option and click on '**Reset**'.

  (In case a shareholder is having valid email address, Password will be sent to his / her registered e-mail address).

Voting method for shareholders on i-Vote E-voting portal:

- After successful login, **Bigshare E-voting system** page will appear.
- Click on "**VIEW EVENT DETAILS (CURRENT)**" under '**EVENTS**' option on investor portal.
- Select event for which you are desire to vote under the dropdown option.
- Click on **"VOTE NOW"** option which is appearing on the right-hand side top corner of the page.
- Cast your vote by selecting an appropriate option "**IN FAVOUR**", "**NOT IN FAVOUR**" or "**ABSTAIN**" and click on "**SUBMIT VOTE**". A confirmation box will be displayed. Click "**OK**" to confirm, else "**CANCEL**" to modify. Once you confirm, you will not be allowed to modify your vote.
- Once you confirm the vote you will receive confirmation message on display screen and also you will receive an email on your registered email id. During the voting period, members can login any number of times till they have voted on the resolution(s). Once vote on a resolution is casted, it cannot be changed subsequently.
- Shareholder can "**CHANGE PASSWORD**" or "**VIEW/UPDATE PROFILE**" under "**PROFILE**" option on investor portal.

2. Custodian registration process for i-Vote E-Voting Website:

- You are requested to launch the URL on internet browser: https://ivote.bigshareonline.com
- Click on "**REGISTER**" under "**CUSTODIAN LOGIN**", to register yourself on Bigshare i-Vote e-Voting Platform.
- Enter all required details and submit.
- After Successful registration, message will be displayed with **"User id and password will be sent via email on your registered email id"**.

  NOTE: If Custodian have registered on to e-Voting system of https://ivote.bigshareonline.com and/or voted on an earlier event of any company then they can use their existing user id and password to login.
- If you have forgotten the password: Click on '**LOGIN**' under '**CUSTODIAN LOGIN**' tab and further Click on '**Forgot your password**?
- Enter "**User ID"** and "**Registered email ID**" Click on **I AM NOT A ROBOT (CAPTCHA)** option and click on '**RESET**.

  (In case a custodian is having valid email address, Password will be sent to his / her registered e-mail address).

Voting method for Custodian on i-Vote E-voting portal:

- After successful login, **Bigshare E-voting system** page will appear.

Investor Mapping:

- First you need to map the investor with your user ID under "**DOCUMENTS**" option on custodian portal.
  - Click on "**DOCUMENT TYPE**" dropdown option and select document type power of attorney (POA).
  - Click on upload document "**CHOOSE FILE**" and upload power of attorney (POA) or board resolution for respective investor and click on "**UPLOAD**".

Note: The power of attorney (POA) or board resolution has to be named as the "**InvestorID.pdf**" (Mention Demat account number as Investor ID.)

- Your investor is now mapped and you can check the file status on display.

Investor vote File Upload:

- To cast your vote, select "**VOTE FILE UPLOAD**" option from left hand side menu on custodian portal.
- Select the Event under dropdown option.
- Download sample voting file and enter relevant details as required and upload the same file under upload document option by clicking on "**UPLOAD**". Confirmation message will be displayed on the screen and also you can check the file status on display (Once vote on a resolution is casted, it cannot be changed subsequently).
- Custodian can "**CHANGE PASSWORD**" or "**VIEW/UPDATE PROFILE**" under "**PROFILE**" option on custodian portal.

Helpdesk for queries regarding e-voting:

Login type	**Helpdesk details**
Shareholders other than individual shareholders holding shares in Demat mode & Physical mode.	In case shareholders/ investor have any queries regarding E-voting, you may refer the Frequently Asked Questions ('FAQs') and i-Vote e-Voting module available at https://ivote.bigshareonline.com, under download section or you can email us to ivote@bigshareonline.com or call us at: 022-62638338

ATTENDANCE SLIP FOR ANNUAL GENERAL MEETING

(To be surrendered at the venue of the meeting)

I certify that I am a registered shareholder/proxy/representative for the registered shareholder(s) of Goldline Pharmaceutical Limited. I hereby record my presence at the 22nd Annual General Meeting of the shareholders of Goldline Pharmaceutical Limited held on Saturday, 29th August, 2026 at 04:00 P.M at the Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025.

Reg. Folio No. / Client ID	
DP ID	
No. of Shares	

Name & Address of Member;

____

Signature of Shareholder/Proxy/Representative

(Please Specify)

Form No. MGT-11

PROXY FORM

[Pursuant to section 105 (6) of the Companies Act, 2013 and rule 19 (3) of the Companies (Management and Administration) Rules, 2014]

CIN	L51397MH2004PLC147806
Name of the Company	GOLDLINE PHARMACEUTICAL LIMITED
Registered office	103, F-1, Leela Apartment Shilpa Hsg Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, India, 440015
Name of the member(s)	
Registered Address	
Email Id	
Folio No / Client ID	DP ID:

I /We, being the member(s) of _________________ shares of the above-named company, hereby appoint

1.	Name			
	Address		Signature	
	Email Id			
	Or failing him			
2.	Name			
	Address		Signature	
	Email Id			
	Or failing him			

as my / our proxy to attend and vote (on a poll) for me / us and on my / our behalf at the 22nd Annual General Meeting of the Company to be held on Saturday, 29th August, 2026 at 4:00 P.M at the Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025, and at any adjournment thereof in respect of such resolutions as are indicated below:

	For	**Against**
Ordinary Business:		
1. To receive, consider and adopt the Standalone Audited Balance Sheet for the year ended 31st March, 2026, the Profit and Loss account for the year ended as on the said date, the Directors' Report and the Auditors' Report thereon.		
2. To declare dividend on preference shares for the financial year 2025-26.		
3. To re-appoint Mr. Prashant Shrikrishna Karkare, Director (DIN: 06572686) who retires by rotation and being eligible, offers herself for the re- appointment.		
Special Business:		
4. To approve existing as well as new material related party transactions with Activista Healthcare Private Limited.		
5. To approve existing as well as new material related party transactions with Nucleage Pharma Solutions Private Limited.		
6. To approve existing as well as new material related party transactions with Numerius Healthcare Private Limited.		

7. Borrowing of Unsecured Loan from directors with an Option of Convertibility into Equity Shares.		
8. Approval of loans, investments, guarantee or security u/s 185 of Companies Act, 2013.		

Signed this …………. day of.................................... 2026.

Signature of shareholder:___________Signature of Proxy holder(s): ___________

Affix

Revenue

Stamp

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Explanatory Statement

(Pursuant to Section 102(1) of the Companies Act, 2013 and Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015)

ITEM NO. 04:

Details of the existing as well as new material related party transactions with Activista Healthcare Private Limited, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are as follows:

(a) name of the related party;	**Activista Healthcare Private Limited**
(b) Nature of relationship [including nature of its interest (financial or otherwise)]	Enterprises over which relatives of KMP are able to exercise significant influence. Mr. Swapan Khandelwal (Whole Time Director), of the Company is a Director of Activista Healthcare Private Limited.
c) Type and particulars of proposed transactions;	• Sale of Goods
d) the material terms of the contract or arrangement including the value, if any;	Transactions in the ordinary course of business with terms and conditions that are generally prevalent in the industry segments and the market that the Company operates in.
e) Tenure of the proposed transactions	Ongoing Transaction exact Tenure undeterminable
f) Value of the proposed transaction	Ongoing Transaction exact value undeterminable.

g) Total transactions for past three years	• FY 25-26: Rs. 113.00 lakhs • FY 24-25: Rs. 245.88 Lakhs • FY 23-24: Rs. 392.68 Lakhs
h) Percentage of Goldline Pharmaceutical Limited annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction.	The Value of the proposed transaction are undetermined therefore the exact percentage of the annual consolidated turnover undeterminable.
i) Justification of the proposed transaction	The proposed transactions are undertaken in the ordinary course of business and on an arm's length basis, considering the commercial requirements of the Company. These entities act as distributors/marketing partners for the Company's products and facilitate wider market reach, availability of products to stockists and customers, and efficient distribution of goods. The transactions enable the Company to leverage the established distribution network, market presence, and operational capabilities of these parties, resulting in improved sales realization, timely movement of goods, and expansion of the Company's business activities.

j) A statement that the valuation or other external report, if any, relied upon by the listed entity in relation to the proposed transaction will be made available through the registered email addresses of the shareholders	The Company conducts transactions with related parties in its ordinary course of business at prices which are at arm's length. The pricing for such transactions is established generally considering market price for comparable transactions with unrelated parties where available or on cost plus reasonable margin basis.
k) Name of the Director or Key Managerial Personnel, who is related	1. Mr. Swapan Khandelwal

ITEM NO. 05:

Details of the existing as well as new material related party transactions with Nucleage Pharma Solutions Private Limited, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are as follows:

(a) name of the related party;	**Nucleage Pharma Solutions Private Limited**
(b) Nature of relationship [including nature of its interest (financial or otherwise)]	Enterprises over which relatives of KMP are able to exercise significant influence. Mr. Swapan Khandelwal (Whole Time Director), of the Company are the Director of Nucleage Pharma Solutions Private Limited.
c) Type and particulars of proposed transactions;	• Sale of Goods

d) the material terms of the contract or arrangement including the value, if any;	Transactions in the ordinary course of business with terms and conditions that are generally prevalent in the industry segments and the market that the Company operates in.
e) Tenure of the proposed transactions	Ongoing Transaction exact Tenure undeterminable
f) Value of the proposed transaction	Ongoing Transaction exact value undeterminable.
g) Total transactions for past three years	• FY 25-26: Rs. 555.64 Lakhs • FY 24-25: Rs. 256.23 Lakhs • FY 23-24: Rs. 122.68 Lakhs
h) Percentage of Goldline Pharmaceutical Limited annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction.	The Value of the proposed transaction are undetermined therefore the exact percentage of the annual consolidated turnover undeterminable.
i) Justification of the proposed transaction	The proposed transactions are undertaken in the ordinary course of business and on an arm's length basis, considering the commercial requirements of the Company. These entities act as distributors/marketing partners for the Company's products and facilitate wider market reach, availability of products to stockists and customers, and efficient distribution of goods. The transactions enable the Company to leverage the established distribution network, market presence, and operational capabilities of these parties, resulting in improved sales realization, timely movement of goods, and expansion of the Company's business activities.

j) A statement that the valuation or other external report, if any, relied upon by the listed entity in relation to the proposed transaction will be made available through the registered email addresses of the shareholders	The Company conducts transactions with related parties in its ordinary course of business at prices which are at arm's length. The pricing for such transactions is established generally considering market price for comparable transactions with unrelated parties where available or on cost plus reasonable margin basis.
k) Name of the Director or Key Managerial Personnel, who is related	1. Mr. Swapan Khandelwal

ITEM NO. 06:

Details of the existing as well as new material related party transactions with Numerius Healthcare Private Limited, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are as follows:

(a) name of the related party;	**Numerius Healthcare Private Limited**
(b) Nature of relationship [including nature of its interest (financial or otherwise)]	Enterprises over which relatives of KMP are able to exercise significant influence. Mr. Swapan Khandelwal (Whole Time Director), of the Company are the Director of Numerius Healthcare Private Limited.
c) Type and particulars of proposed transactions;	• Sale of Goods

d) the material terms of the contract or arrangement including the value, if any;	Transactions in the ordinary course of business with terms and conditions that are generally prevalent in the industry segments and the market that the Company operates in
e) Tenure of the proposed transactions	Ongoing Transaction exact Tenure undeterminable
f) Value of the proposed transaction	Ongoing Transaction exact value undeterminable.
g) Total transactions for past three years	• FY 25-26: Rs. 1.96 Lakhs • FY 24-25: Rs. 304.33 Lakhs • FY 23-24: Rs. 60.75 Lakhs
h) Percentage of Goldline Pharmaceutical Limited annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction.	The Value of the proposed transaction are undetermined therefore the exact percentage of the annual consolidated turnover undeterminable.
i) Justification of the proposed transaction	The proposed transactions are undertaken in the ordinary course of business and on an arm's length basis, considering the commercial requirements of the Company. These entities act as distributors/marketing partners for the Company's products and facilitate wider market reach, availability of products to stockists and customers, and efficient distribution of goods. The transactions enable the Company to leverage the established distribution network, market presence, and operational capabilities of these parties, resulting in improved sales realization, timely movement of goods, and expansion of the Company's business activities.

j) A statement that the valuation or other external report, if any, relied upon by the listed entity in relation to the proposed transaction will be made available through the registered email addresses of the shareholders	The Company conducts transactions with related parties in its ordinary course of business at prices which are at arm's length. The pricing for such transactions is established generally considering market price for comparable transactions with unrelated parties where available or on cost plus reasonable margin basis.
k) Name of the Director or Key Managerial Personnel, who is related	1. Mr. Swapan Khandelwal

ITEM NO. 07:

Pursuant to the following terms being agreed between the Company and its Directors and the recommendation of Audit Committee and Section 62 (3) read with other applicable provisions, if any, including SEBI regulations and in accordance with the Memorandum and Articles of Association of the Company, it is proposed to borrow unsecured loan from the Directors of the Company as and when required subject to overall limit of borrowing of Rs. 200 Crores as sanctioned under Section 180 (1) (c) of the Companies Act, 2013.

Further, the conversion right attached with the unsecured loan of Directors is proposed to be approved to convert the whole or part of the outstanding loan at the option of Directors into fully paid up equity shares of the Company on the following terms and conditions:

Terms & Conditions:

I. the conversion right reserved as aforesaid may be exercised by the Directors during the continuation of loan;

II. on receipt of the notice of conversion, the Company shall subject to the terms being entered, allot and issue the requisite number of fully paid-up equity shares to the Directors and the Directors may accept the same in satisfaction of the part of the loans so converted;

III. the part of the loan so converted shall cease to carry interest as from the date of conversion and the loan shall stand correspondingly reduced. Upon such conversion, the repayment instalments of the loan payable after the date of conversion as per the terms shall stand reduced proportionately by the amount of the loan so converted. The equity shares so allotted and issued to the Directors shall rank pari passu with the existing equity shares of the Company in all respects.

IV. in the event the Directors exercise the conversion right as aforesaid, the Company shall at its cost get the equity shares, issued to the Directors and list the shares on the Stock exchanges where Company's shares are presently listed and for the said purpose the Company shall take all such steps as may be necessary to ensure that the equity shares are listed on the Stock Exchanges.

V. the loan shall be converted into equity shares at a price to be determined in accordance with the applicable Securities and Exchange Board of India Regulations at the time of such conversion.

VI. the equity shares so allotted pursuant to conversion shall call carry right to receive the dividends and other distributions to be declared in respect of paid up equity share capital of the Company.

Further, in accordance with the provisions of the Companies Act, 2013, the company shall require to obtain the approval of shareholders by special resolution, for the conversion of the loan into equity shares of the company.

The Board of Directors recommends the passing of this resolution as set out at Item No. 6 of the notice by Special resolution.

None of the Directors, Key Managerial Personnel, relatives of Directors and Key Managerial Personnel of the Company is directly/ indirectly interested in the above resolution except to the extent of their respective interest as shareholders of the Company.

ITEM NO. 08:

The Company is expected to render support for the business requirements of other companies in the group, from time to time. However, owing to certain restrictive provisions contained in the Section 185 of the Companies Act, 2013, the Company was unable to extend financial assistance by way of loan, guarantee or security. In the light of amendments notified effective May 7, 2018, inter-alia replacing the provisions Section 185 of Companies Act, 2013, the Company with the approval of members by way of special resolution, would be in a position to provide financial assistance by way of loan to other entities in the group or give guarantee or provide security in respect of loans taken by such entities, for their principal business activities. The members may note that board of directors would carefully evaluate proposals and provide such loan, guarantee or security proposals through deployment of funds out of internal resources / accruals and / or any other appropriate sources, from time to time, only for principal business activities of the entities. Hence, in order to enable the company to advance loan to Managing Director/Whole Time Director/Subsidiaries/ Joint Ventures /associates/ other Companies/ Firms in which Directors are interested directly or indirectly under section 185 of the Companies Act, 2013 requires approval of members by a Special Resolution. The Board of Directors Recommend the Special Resolution for approval by the members. None of the Director, KMP and their relatives is in any way concerned or interested financially or otherwise in this resolution except to the extent of their shareholding.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

SD/-

Name: Amol Laxmikant Mujumdar
DIN: 01910549
Designation: Managing Director
Date: 06/08/2026
Place: Nagpur

Details of Director seeking re-appointment at the Annual General Meeting

(In pursuance of Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard – 2 on General Meetings)

Name of the Director	Prashant Shrikrishna Karkare
Director Identification Number (DIN)	06572686
Designation and Category of Director	Executive Director
Date of birth and age	26/03/1966 (60 Years)
Date of appointment	Appointed as Member of the Board on July 16, 2013
Qualifications	B.Sc.
Brief profile	**Mr. Prashant Shrikrishna Karkare** is the Executive Director of Goldline Pharmaceutical Limited and has been serving on the Board since **July 16, 2013**. He holds a Bachelor's degree in Science from Nagpur University and brings more than **30 years of rich experience** in the pharmaceutical industry. Prior to his appointment as Executive Director, he served as the Company's General Manager – Marketing and has held key positions with reputed pharmaceutical companies, including Kappac Pharma Limited, Paraan Limited and Cipla Limited. At Goldline Pharmaceutical Limited, he is responsible for leading the sales and marketing functions, driving business growth, strengthening customer relationships and overseeing the implementation of the Company's risk management policies. His extensive industry knowledge, strategic leadership and operational expertise have significantly contributed to the Company's sustained growth and market presence.

Expertise in specific functional areas	Rich experience in various areas of business, technology, operations, societal and governance matters
Terms and conditions of re-appointment	Re-appointment in terms of Section 152(6) of the Companies Act, 2013
Directorships held in other companies (excluding Foreign Companies)	NIL
Listed Entities from which he has resigned as Director in past 3 years	None
Memberships/Chairmanships of committees of other companies	NIL
Number of Equity Shares held in the Company	27003
Number of Meetings of the Board attended during The FY 2025-26	9
Past Remuneration	Rs.11.78 Lakhs
Relationship with other Directors and Key Managerial Personnel,	Mr. Prashant Shrikrishna Karkare as Executive Director of the Company has no other relationship with the Company